IPM Take
For decades, many patients have met cardiology at the wrong end of the disease pathway.
Chest pain appears. Exercise becomes difficult. A heart attack happens. Then the specialist enters.
Modern prevention is trying to reverse that sequence.
But the answer is not to turn cardiologists into routine screening doctors for everyone.
For people with normal blood pressure, healthy lipid levels, no significant symptoms, no concerning family history and a favourable overall risk profile, primary care can usually manage cardiovascular prevention. The more important policy challenge is making sure primary care has the tools, time and referral pathways to recognise the people who do need something more.
That group is becoming easier to define.
The 2026 ACC/AHA dyslipidaemia guideline recommends earlier assessment across the life course, use of the PREVENT equations for 10-year and 30-year risk, at least one lifetime lipoprotein(a) measurement in adults and selective use of coronary artery calcium and other biomarkers where conventional risk assessment leaves uncertainty.
In other words, preventive cardiology is becoming less about waiting for disease and more about identifying the trajectory toward it.
The question should not be, “Should everyone see a cardiologist?”
It should be, “Can the health system identify cardiovascular risk early enough to know who needs one?”
Executive Summary
A People health feature published on 2 October highlights five circumstances in which a cardiology assessment may deserve consideration: a strong family history of cardiovascular disease, concerning symptoms, abnormal cardiovascular risk markers, changes around menopause and a combination of lifestyle-related risk factors.
The article makes an important distinction that is sometimes lost in consumer cardiovascular messaging: preventive cardiology is valuable, but routine specialist appointments are not necessary for every healthy adult. Primary care remains the natural starting point for most cardiovascular risk assessment.
That distinction has become more important following major changes in US preventive guidance.
The 2026 ACC/AHA dyslipidaemia guideline now recommends use of the AHA’s PREVENT-ASCVD equations for adults aged 30 to 79 without known cardiovascular disease, allowing clinicians to assess both shorter-term and longer-term risk.
It also recommends that Lp(a), a largely genetically determined cardiovascular risk factor, be measured at least once in adulthood. Family history, chronic kidney disease, diabetes, obesity and reproductive factors can further modify the interpretation of risk.
This creates a more sophisticated prevention pathway than simply waiting for cholesterol, blood pressure or symptoms to become severe.
But it also creates an implementation problem: risk detection is becoming more complex at the same time that specialist capacity is finite.
The logical response is not universal cardiology referral.
It is better triage.
Why it matters
- HTA bodies: Earlier cardiovascular risk assessment may expand the use of biomarkers, coronary calcium imaging and preventive therapies. Assessment will increasingly need to consider whether additional testing meaningfully changes management and outcomes rather than merely identifying more abnormalities.
- Payers: Better risk stratification could move expenditure upstream, toward testing and preventive treatment before cardiovascular events occur. The economic question is whether targeted earlier intervention reduces expensive downstream events without creating unnecessary specialist consultations and testing in low-risk populations.
- Industry / innovation partners: Expanding use of Lp(a), apoB, coronary calcium imaging and digital risk tools creates opportunities across diagnostics and prevention. But technologies will need to fit into clear referral pathways. Detecting additional risk is useful only if clinicians know what action should follow.
There is a familiar pattern in cardiovascular medicine.
Patients often arrive at cardiology because something has already gone wrong.
A symptom appeared. A blood test became concerning. An ECG looked abnormal. A relative had a heart attack and suddenly family history felt more urgent.
The underlying cardiovascular process may have been developing for years.
That is why preventive cardiology is moving steadily upstream.
The challenge is deciding how far upstream specialist care should go.
The goal is not a cardiologist for everyone
Consumer health messaging can make specialist care sound inherently better than primary care.
Cardiovascular prevention does not work that way.
For someone with normal blood pressure, favourable cholesterol, no symptoms, no major family history and otherwise low estimated cardiovascular risk, routine primary care can usually provide appropriate prevention.
That is not a lesser form of cardiovascular medicine.
It is how an efficient prevention system should work.
Primary care can identify hypertension, diabetes, dyslipidaemia, smoking, obesity and other major risk factors long before most patients need specialist intervention.
Cardiology becomes particularly valuable when risk is high, unclear or difficult to manage, when symptoms require specialist investigation, or when inherited and structural cardiovascular disease becomes a concern.
The problem is that traditional referral pathways have not always been good at detecting those patients early.
Family history is becoming harder to dismiss
One of the clearest examples is premature cardiovascular disease in a close relative.
A heart attack in a parent or sibling at an unusually young age can point toward inherited risk that may not be obvious from someone’s appearance, activity level or routine cholesterol panel.
Familial hypercholesterolaemia is one example.
Lp(a) is another.
Lp(a) attracted much more attention in the 2026 dyslipidaemia guideline because its concentration is largely inherited, remains relatively stable over life and can materially increase a person’s atherosclerotic cardiovascular risk.
The new recommendation is straightforward: adults should have it measured at least once.
That is a significant change in preventive practice.
For years, many people with elevated Lp(a) would never know because the test is not part of a standard lipid panel.
Now the policy question becomes what happens after an elevated result is found.
For many patients, the response will involve more intensive management of modifiable risk factors rather than immediate specialist treatment.
For people with very high levels, premature family disease or a complex risk profile, cardiology or lipid-specialist referral may become more relevant.
Screening creates value only when the pathway after screening is clear.
Risk assessment is becoming longer-term
Another change is the move away from asking only whether somebody is likely to have a cardiovascular event within the next decade.
A 35-year-old with hypertension, high LDL cholesterol or a strong family history may still appear relatively low risk over ten years simply because they are young.
That does not mean decades of exposure are benign.
The AHA’s PREVENT equations estimate both 10-year and, for appropriate age groups, 30-year cardiovascular risk by incorporating cardiovascular, kidney and metabolic information.
That changes the prevention conversation.
It allows clinicians to ask not only whether a patient is likely to have a heart attack soon, but whether the current trajectory is building substantial lifetime risk.
This is particularly relevant for younger adults who may otherwise be reassured by age alone.
Symptoms still change everything
Prevention should not blur the distinction between risk assessment and symptom evaluation.
Chest discomfort, unexplained shortness of breath, declining exercise tolerance, palpitations and leg swelling can all warrant medical assessment.
Severe or acute symptoms are not reasons to book a routine preventive cardiology visit and wait.
They can require urgent evaluation.
That distinction sounds obvious, but it matters when cardiovascular information increasingly reaches patients through consumer media, apps and online risk tools.
A prevention system has to communicate both messages at once:
Do not wait for symptoms before thinking about cardiovascular risk.
But when serious symptoms appear, do not treat them as a prevention appointment.
Menopause is a checkpoint, not an automatic referral
Women’s cardiovascular prevention exposes another weakness in simplistic referral rules.
Cardiovascular risk factors can change during midlife and menopause. LDL cholesterol, blood pressure, body composition and metabolic risk may worsen, while reproductive history can contain information relevant to later cardiovascular risk.
The 2026 dyslipidaemia guideline explicitly incorporates reproductive risk-enhancing factors into personalised assessment.
But menopause itself is not a disease and does not automatically create a need for cardiology referral.
A better approach is to use this stage of life as a cardiovascular checkpoint.
Blood pressure, lipid profile, glucose status, smoking, family history and other risk factors can be reviewed. Previous pregnancy complications and premature menopause may add information.
Specialist involvement should then depend on the risk that assessment reveals.
That is risk-based care rather than referral by demographic category.
More testing can also create more medicine
There is another side to earlier detection.
Once healthcare systems start looking for more cardiovascular risk, they will inevitably find more of it.
Lp(a), apoB, coronary calcium imaging and sophisticated risk calculators can refine prevention.
They can also generate additional testing, specialist visits and anxiety if used without clear indications.
The 2026 guideline tries to avoid that by using a staged model.
Calculate baseline risk.
Personalise it using additional risk-enhancing factors.
Then use tests such as coronary artery calcium selectively when uncertainty remains and the result could change treatment.
That logic matters for policy.
The goal of precision prevention is not to perform every possible cardiovascular test.
It is to perform the test that changes the decision.
Primary care becomes more important, not less
As prevention becomes more sophisticated, it would be easy to conclude that more care should migrate to specialists.
The opposite may be necessary.
Routine cardiovascular risk assessment has to work at scale.
That means primary-care teams need access to current risk calculators, appropriate laboratory testing, decision support and rapid specialist referral when results fall outside straightforward management.
Cardiologists can then concentrate on complex risk, difficult-to-control disease, inherited cardiovascular conditions and diagnostic uncertainty.
That kind of division matters because specialist capacity is not unlimited.
Using cardiology appointments for low-risk routine screening while patients with genuine high-risk findings wait months for specialist review would be the opposite of prevention.
The real prevention gap sits before the referral
The debate over who “needs a cardiologist” therefore misses something.
A patient cannot be referred appropriately if nobody has recognised the risk.
Someone with high blood pressure but no symptoms may never seek care.
Someone with high LDL cholesterol in their twenties may be told they are too young to worry.
Someone with inherited Lp(a) elevation may never be tested.
Someone with a strong family history may not realise it changes their own risk.
These are failures that occur before specialist care enters the picture.
The emerging prevention model is therefore less about opening the cardiology door wider and more about building a better route to that door.
Routine risk assessment should happen early.
Primary care should manage what it can.
Specialist care should become easier to access when risk, symptoms or diagnostic uncertainty justify it.
The future of preventive cardiology is not getting everyone into a cardiologist’s office. It is making sure the right people arrive before cardiovascular disease does.
